|
US5470571A
(en)
|
1988-01-27 |
1995-11-28 |
The Wistar Institute |
Method of treating human EGF receptor-expressing gliomas using radiolabeled EGF receptor-specific MAB 425
|
|
FR2660556B1
(fr)
|
1990-04-06 |
1994-09-16 |
Rhone Poulenc Sante |
Microspheres, leur procede de preparation et leur utilisation.
|
|
IL98528A0
(en)
|
1990-06-21 |
1992-07-15 |
Merck & Co Inc |
Pharmaceutical compositions containing hybrid for killing bladder cancer cells
|
|
KR100240308B1
(ko)
|
1991-03-06 |
2000-01-15 |
플레믹 크리스티안 |
인간화된단클론성항체및혼성단클론성항체
|
|
US6515009B1
(en)
|
1991-09-27 |
2003-02-04 |
Neorx Corporation |
Therapeutic inhibitor of vascular smooth muscle cells
|
|
US5811447A
(en)
|
1993-01-28 |
1998-09-22 |
Neorx Corporation |
Therapeutic inhibitor of vascular smooth muscle cells
|
|
CA2086874E
(en)
|
1992-08-03 |
2000-01-04 |
Renzo Mauro Canetta |
Methods for administration of taxol
|
|
US6306421B1
(en)
|
1992-09-25 |
2001-10-23 |
Neorx Corporation |
Therapeutic inhibitor of vascular smooth muscle cells
|
|
US5981568A
(en)
|
1993-01-28 |
1999-11-09 |
Neorx Corporation |
Therapeutic inhibitor of vascular smooth muscle cells
|
|
US6491938B2
(en)
|
1993-05-13 |
2002-12-10 |
Neorx Corporation |
Therapeutic inhibitor of vascular smooth muscle cells
|
|
US5362478A
(en)
|
1993-03-26 |
1994-11-08 |
Vivorx Pharmaceuticals, Inc. |
Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell
|
|
US6096331A
(en)
*
|
1993-02-22 |
2000-08-01 |
Vivorx Pharmaceuticals, Inc. |
Methods and compositions useful for administration of chemotherapeutic agents
|
|
US6753006B1
(en)
|
1993-02-22 |
2004-06-22 |
American Bioscience, Inc. |
Paclitaxel-containing formulations
|
|
US5997904A
(en)
|
1993-02-22 |
1999-12-07 |
American Bioscience, Inc. |
Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof
|
|
US5439686A
(en)
|
1993-02-22 |
1995-08-08 |
Vivorx Pharmaceuticals, Inc. |
Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
|
|
US5665383A
(en)
|
1993-02-22 |
1997-09-09 |
Vivorx Pharmaceuticals, Inc. |
Methods for the preparation of immunostimulating agents for in vivo delivery
|
|
US5650156A
(en)
|
1993-02-22 |
1997-07-22 |
Vivorx Pharmaceuticals, Inc. |
Methods for in vivo delivery of nutriceuticals and compositions useful therefor
|
|
US5665382A
(en)
|
1993-02-22 |
1997-09-09 |
Vivorx Pharmaceuticals, Inc. |
Methods for the preparation of pharmaceutically active agents for in vivo delivery
|
|
US6537579B1
(en)
|
1993-02-22 |
2003-03-25 |
American Bioscience, Inc. |
Compositions and methods for administration of pharmacologically active compounds
|
|
US20030068362A1
(en)
|
1993-02-22 |
2003-04-10 |
American Bioscience, Inc. |
Methods and formulations for the delivery of pharmacologically active agents
|
|
US5916596A
(en)
|
1993-02-22 |
1999-06-29 |
Vivorx Pharmaceuticals, Inc. |
Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
|
|
US5498421A
(en)
|
1993-02-22 |
1996-03-12 |
Vivorx Pharmaceuticals, Inc. |
Composition useful for in vivo delivery of biologics and methods employing same
|
|
US6749868B1
(en)
|
1993-02-22 |
2004-06-15 |
American Bioscience, Inc. |
Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
|
|
US6528067B1
(en)
|
1993-02-22 |
2003-03-04 |
American Bioscience, Inc. |
Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof
|
|
DE69435002T2
(de)
|
1993-07-19 |
2008-03-20 |
Angiotech Pharmaceuticals, Inc., Vancouver |
Anti-angiogene Mittel enthaltend Taxol und einen nicht biodegradierbaren Träger und deren Verwendung
|
|
US5886026A
(en)
|
1993-07-19 |
1999-03-23 |
Angiotech Pharmaceuticals Inc. |
Anti-angiogenic compositions and methods of use
|
|
US6441026B1
(en)
|
1993-11-08 |
2002-08-27 |
Aventis Pharma S.A. |
Antitumor compositions containing taxane derivatives
|
|
AU1831395A
(en)
|
1994-01-14 |
1995-08-01 |
Cell Therapeutics, Inc. |
Method for treating diseases mediated by cellular proliferation in response to pdgf, egf, fgf and vegf
|
|
US5626862A
(en)
|
1994-08-02 |
1997-05-06 |
Massachusetts Institute Of Technology |
Controlled local delivery of chemotherapeutic agents for treating solid tumors
|
|
US5662883A
(en)
|
1995-01-10 |
1997-09-02 |
Nanosystems L.L.C. |
Microprecipitation of micro-nanoparticulate pharmaceutical agents
|
|
US5534270A
(en)
|
1995-02-09 |
1996-07-09 |
Nanosystems Llc |
Method of preparing stable drug nanoparticles
|
|
US5510118A
(en)
|
1995-02-14 |
1996-04-23 |
Nanosystems Llc |
Process for preparing therapeutic compositions containing nanoparticles
|
|
US5609629A
(en)
|
1995-06-07 |
1997-03-11 |
Med Institute, Inc. |
Coated implantable medical device
|
|
AU716005B2
(en)
|
1995-06-07 |
2000-02-17 |
Cook Medical Technologies Llc |
Implantable medical device
|
|
US6565842B1
(en)
|
1995-06-07 |
2003-05-20 |
American Bioscience, Inc. |
Crosslinkable polypeptide compositions
|
|
US5744460A
(en)
|
1996-03-07 |
1998-04-28 |
Novartis Corporation |
Combination for treatment of proliferative diseases
|
|
US5977163A
(en)
|
1996-03-12 |
1999-11-02 |
Pg-Txl Company, L. P. |
Water soluble paclitaxel prodrugs
|
|
US6441025B2
(en)
|
1996-03-12 |
2002-08-27 |
Pg-Txl Company, L.P. |
Water soluble paclitaxel derivatives
|
|
US6239124B1
(en)
|
1996-07-30 |
2001-05-29 |
Novartis Ag |
Pharmaceutical compositions for the treatment of transplant rejection or autoimmune or inflammatory conditions comprising cyclosporin A and 40-0-(2-hydroxyethyl)-rapamycin
|
|
CA2263765C
(en)
|
1996-08-19 |
2010-03-30 |
Vivorx Pharmaceuticals, Inc. |
Methods for the production of protein particles useful for delivery of pharmacological agents
|
|
US8137684B2
(en)
|
1996-10-01 |
2012-03-20 |
Abraxis Bioscience, Llc |
Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
|
|
US6495579B1
(en)
|
1996-12-02 |
2002-12-17 |
Angiotech Pharmaceuticals, Inc. |
Method for treating multiple sclerosis
|
|
US6143276A
(en)
|
1997-03-21 |
2000-11-07 |
Imarx Pharmaceutical Corp. |
Methods for delivering bioactive agents to regions of elevated temperatures
|
|
US6884879B1
(en)
|
1997-04-07 |
2005-04-26 |
Genentech, Inc. |
Anti-VEGF antibodies
|
|
KR100870353B1
(ko)
|
1997-04-07 |
2008-11-25 |
제넨테크, 인크. |
항-ｖｅｇｆ 항체
|
|
US20030199425A1
(en)
|
1997-06-27 |
2003-10-23 |
Desai Neil P. |
Compositions and methods for treatment of hyperplasia
|
|
KR100904931B1
(ko)
|
1997-06-27 |
2009-06-29 |
아브락시스 바이오사이언스, 엘엘씨 |
나노 입자 및 그의 제조 방법
|
|
US8853260B2
(en)
|
1997-06-27 |
2014-10-07 |
Abraxis Bioscience, Llc |
Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
|
|
US6258084B1
(en)
|
1997-09-11 |
2001-07-10 |
Vnus Medical Technologies, Inc. |
Method for applying energy to biological tissue including the use of tumescent tissue compression
|
|
GB9800569D0
(en)
|
1998-01-12 |
1998-03-11 |
Glaxo Group Ltd |
Heterocyclic compounds
|
|
EP1071440B1
(en)
|
1998-04-16 |
2007-01-03 |
Eurovita A/S |
Novel synergistic compositions containing aromatic compounds and terpenoids present in alpinia galanga
|
|
WO2000006152A1
(en)
|
1998-07-30 |
2000-02-10 |
Novopharm Biotech, Inc. |
Pharmaceutically acceptable composition comprising an aqueous solution of paclitaxel and albumin
|
|
US6682758B1
(en)
|
1998-12-22 |
2004-01-27 |
The United States Of America As Represented By The Department Of Health And Human Services |
Water-insoluble drug delivery system
|
|
US6537585B1
(en)
|
1999-03-26 |
2003-03-25 |
Guilford Pharmaceuticals, Inc. |
Methods and compositions for treating solid tumors
|
|
AU777528B2
(en)
|
1999-04-22 |
2004-10-21 |
Abraxis Bioscience, Llc |
Long term administration of pharmacologically active agents
|
|
HK1045646A1
(zh)
|
1999-05-21 |
2002-12-06 |
Abraxis Bioscience, Llc |
蛋白質穩定化的藥理學活性劑，其製備方法及其使用方法
|
|
CA2373994A1
(en)
|
1999-05-24 |
2000-11-30 |
Sonus Pharmaceuticals, Inc. |
Emulsion vehicle for poorly soluble drugs
|
|
AU1916301A
(en)
|
1999-11-12 |
2001-06-06 |
Children's Medical Center Corporation |
Methods for administration of therapeutic agents on an antiangiogenic schedule
|
|
US7740841B1
(en)
|
2000-01-28 |
2010-06-22 |
Sunnybrook Health Science Center |
Therapeutic method for reducing angiogenesis
|
|
WO2001076567A1
(en)
|
2000-04-10 |
2001-10-18 |
Teva Pharmaceutical Industries Ltd. |
Method and composition for treating cancer by administration of apoptosis-inducing chemotherapeutic agents
|
|
ITMI20001107A1
(it)
|
2000-05-18 |
2001-11-18 |
Acs Dobfar Spa |
Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel
|
|
IL153111A0
(en)
|
2000-06-30 |
2003-06-24 |
Glaxo Group Ltd |
Quinazoline ditosylate salt compounds
|
|
ATE526019T1
(de)
|
2000-07-28 |
2011-10-15 |
Sloan Kettering Inst Cancer |
Verfahren zur behandlung von zellproliferationen störungen und virusinfektionen
|
|
AU2001288805A1
(en)
|
2000-09-22 |
2002-04-02 |
Bristol-Myers Squibb Company |
Method for reducing toxicity of combined chemotherapies
|
|
DE60203260T2
(de)
|
2001-01-16 |
2006-02-02 |
Glaxo Group Ltd., Greenford |
Pharmazeutische kombination, die ein 4-chinazolinamin und paclitaxel, carboplatin oder vinorelbin enthält, zur behandlung von krebs
|
|
US6548531B2
(en)
|
2001-02-09 |
2003-04-15 |
Hoffmann-La Roche Inc. |
Method for cancer therapy
|
|
GB0103668D0
(en)
|
2001-02-15 |
2001-03-28 |
Biointeractions Ltd |
Methods and clinical devices for the inhibition or prevention of mammalian cell growth
|
|
WO2002069949A2
(en)
*
|
2001-03-06 |
2002-09-12 |
Prendergast Patrick T |
Combination therapy for reduction of toxycity of chemotherapeutic agents
|
|
EP1368034A1
(en)
|
2001-03-06 |
2003-12-10 |
Bristol-Myers Squibb Company |
Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin
|
|
US6752922B2
(en)
|
2001-04-06 |
2004-06-22 |
Fluidigm Corporation |
Microfluidic chromatography
|
|
US7638161B2
(en)
|
2001-07-20 |
2009-12-29 |
Applied Materials, Inc. |
Method and apparatus for controlling dopant concentration during BPSG film deposition to reduce nitride consumption
|
|
US6872715B2
(en)
|
2001-08-06 |
2005-03-29 |
Kosan Biosciences, Inc. |
Benzoquinone ansamycins
|
|
US7056338B2
(en)
|
2003-03-28 |
2006-06-06 |
Conor Medsystems, Inc. |
Therapeutic agent delivery device with controlled therapeutic agent release rates
|
|
US20040033271A1
(en)
|
2001-12-03 |
2004-02-19 |
Seth Lederman |
Methods for contemporaneous administration of levamisole and 5-fluorouracil
|
|
US20040143004A1
(en)
|
2002-02-26 |
2004-07-22 |
Joseph Fargnoli |
Metronomic dosing of taxanes
|
|
ITMI20020680A1
(it)
|
2002-03-29 |
2003-09-29 |
Acs Dobfar Spa |
Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento
|
|
ITMI20020681A1
(it)
|
2002-03-29 |
2003-09-29 |
Acs Dobfar Spa |
Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina
|
|
US20040126400A1
(en)
|
2002-05-03 |
2004-07-01 |
Iversen Patrick L. |
Delivery of therapeutic compounds via microparticles or microbubbles
|
|
US20050276812A1
(en)
|
2004-06-01 |
2005-12-15 |
Genentech, Inc. |
Antibody-drug conjugates and methods
|
|
US7794743B2
(en)
|
2002-06-21 |
2010-09-14 |
Advanced Cardiovascular Systems, Inc. |
Polycationic peptide coatings and methods of making the same
|
|
TWI272273B
(en)
|
2002-07-16 |
2007-02-01 |
Sonus Pharma Inc |
Platinum compounds
|
|
CN1681495B
(zh)
|
2002-08-19 |
2010-05-12 |
辉瑞产品公司 |
用于治疗过度增生性疾病的组合物
|
|
US20040047835A1
(en)
*
|
2002-09-06 |
2004-03-11 |
Cell Therapeutics, Inc. |
Combinatorial drug therapy using polymer drug conjugates
|
|
US20050095267A1
(en)
|
2002-12-04 |
2005-05-05 |
Todd Campbell |
Nanoparticle-based controlled release polymer coatings for medical implants
|
|
LT1585548T
(lt)
|
2002-12-09 |
2018-09-25 |
Abraxis Bioscience, Llc |
Farmakologinių agentų kompozicijos ir įvedimo būdai
|
|
BR0317134A
(pt)
|
2002-12-09 |
2005-11-22 |
American Bioscience Inc |
Composições e métodos de liberação de agentes farmacológicos
|
|
AU2004204778B2
(en)
|
2003-01-10 |
2008-05-22 |
Threshold Pharmaceuticals, Inc. |
Treatment of cancer with 2-deoxyglucose
|
|
EP1643971A2
(en)
|
2003-05-22 |
2006-04-12 |
Neopharm, Inc. |
Liposomal formulations comprising a combination of two or more active agents
|
|
KR20160014775A
(ko)
|
2003-05-30 |
2016-02-11 |
제넨테크, 인크. |
항-ｖｅｇｆ 항체를 사용한 치료
|
|
AR046510A1
(es)
|
2003-07-25 |
2005-12-14 |
Regeneron Pharma |
Composicion de un antagonista de vegf y un agente anti-proliferativo
|
|
EP1670477A2
(en)
|
2003-09-18 |
2006-06-21 |
CombinatoRx, Incorporated |
Combinations of drugs for the treatment of neoplasms
|
|
EP1682181A2
(en)
|
2003-09-23 |
2006-07-26 |
Novartis AG |
Combination of a vegf receptor inhibitor with a chemotherapeutic agent
|
|
AU2004283464B8
(en)
|
2003-10-15 |
2011-04-14 |
Syncore Biotechnology Co., Ltd |
Method of administering cationic liposomes comprising an active drug
|
|
KR20060110872A
(ko)
|
2003-10-29 |
2006-10-25 |
소너스파머슈티칼즈인코포레이티드 |
토코페롤 변성 치료제 약물 화합물
|
|
US20080045559A1
(en)
|
2003-10-29 |
2008-02-21 |
Sonus Pharmaceuticals, Inc. |
Tocopherol-modified therapeutic drug compounds
|
|
WO2005090372A2
(en)
|
2004-03-15 |
2005-09-29 |
Sonus Pharmaceuticals, Inc. |
Platinum carboxylate anticancer compounds
|
|
US20060003931A1
(en)
|
2004-05-06 |
2006-01-05 |
Genentech, Inc. |
Crystal structure of the hepatocyte growth factor and methods of use
|
|
WO2005117952A2
(en)
|
2004-05-14 |
2005-12-15 |
Abraxis Bioscience, Inc. |
Treatment methods utilizing albumin-binding proteins as targets
|
|
US8420603B2
(en)
|
2004-05-14 |
2013-04-16 |
Abraxis Bioscience, Llc |
SPARC and methods of use thereof
|
|
BRPI0510915A
(pt)
|
2004-06-04 |
2007-11-13 |
Genentech Inc |
método para o tratamento da esclerose múltipla e artigo manufaturado
|
|
GT200500155A
(es)
|
2004-06-16 |
2006-05-15 |
|
Terapia del càncer resistente al platino
|
|
US8772269B2
(en)
|
2004-09-13 |
2014-07-08 |
Eisai R&D Management Co., Ltd. |
Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
|
|
NZ595313A
(en)
|
2005-02-18 |
2013-03-28 |
Abraxis Bioscience Llc |
The Use Of Nanoparticles Comprising Rapamycin Or Taxane In The Treatment Of Proliferative Diseases
|
|
US8735394B2
(en)
|
2005-02-18 |
2014-05-27 |
Abraxis Bioscience, Llc |
Combinations and modes of administration of therapeutic agents and combination therapy
|
|
CN101160321A
(zh)
|
2005-02-18 |
2008-04-09 |
阿布拉西斯生物科学公司 |
Q3 sparc缺失突变体及其用途
|
|
US20070166388A1
(en)
|
2005-02-18 |
2007-07-19 |
Desai Neil P |
Combinations and modes of administration of therapeutic agents and combination therapy
|
|
JPWO2006090928A1
(ja)
|
2005-02-28 |
2008-07-24 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
スルホンアミド化合物の血管新生阻害物質との新規併用
|
|
JP5700909B2
(ja)
|
2005-05-04 |
2015-04-15 |
メディゲーネ アクチエンゲゼルシャフトＭｅｄｉＧｅｎｅ ＡＧ |
パクリタキセルを含む陽イオン性リポソーム製剤を投与する方法
|
|
US20080221135A1
(en)
|
2005-05-13 |
2008-09-11 |
Bristol-Myers Squibb Company |
Combination therapy
|
|
CN101263142A
(zh)
|
2005-05-20 |
2008-09-10 |
阿雷生物药品公司 |
Raf抑制剂化合物及其使用方法
|
|
KR101643416B1
(ko)
|
2005-08-31 |
2016-07-27 |
아브락시스 바이오사이언스, 엘엘씨 |
증가된 안정성을 가진 수 난용성 약물의 조성물 및 제조방법
|
|
CA2880727C
(en)
|
2005-08-31 |
2019-05-07 |
Neil P. Desai |
Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents
|
|
WO2007059116A2
(en)
|
2005-11-14 |
2007-05-24 |
Abraxis Bioscience, Inc. |
Geldanamycin derivatives and pharmaceutical compositions thereof
|
|
RU2448697C2
(ru)
|
2006-03-22 |
2012-04-27 |
Медигене Аг |
Лечение рака молочной железы, негативного по трем рецепторам
|
|
WO2008021186A2
(en)
|
2006-08-10 |
2008-02-21 |
Global Grid, Llc |
Web based integrated information system for sharing patient medical information cross-organizationally
|
|
MX2009002054A
(es)
|
2006-08-31 |
2009-05-01 |
Abraxis Bioscience Llc |
Metodos para inhibir angiogenesis y tratamiento contra enfermedades asociadas con angiogenesis.
|
|
US20080280987A1
(en)
|
2006-08-31 |
2008-11-13 |
Desai Neil P |
Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
|
|
CA2672618C
(en)
|
2006-12-14 |
2021-03-02 |
Abraxis Bioscience, Llc |
Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
|
|
FR2912839B1
(fr)
|
2007-02-16 |
2009-05-15 |
Soitec Silicon On Insulator |
Amelioration de la qualite de l'interface de collage par nettoyage froid et collage a chaud
|
|
KR20150002886A
(ko)
|
2007-03-07 |
2015-01-07 |
아브락시스 바이오사이언스, 엘엘씨 |
항암제로서 라파마이신 및 알부민을 포함하는 나노입자
|
|
EP3326630A3
(en)
|
2007-05-03 |
2018-08-29 |
Abraxis BioScience, LLC |
Methods and compositions for treating pulmonary hypertension
|
|
AU2008260447B2
(en)
|
2007-06-01 |
2013-10-10 |
Abraxis Bioscience, Llc |
Methods and compositions for treating recurrent cancer
|
|
WO2009009587A2
(en)
|
2007-07-09 |
2009-01-15 |
Board Of Regents Of The University Of Nebraska |
Apoptosis-modulating protein therapy for proliferative disorders and nanoparticles containing the same
|
|
WO2009089098A1
(en)
*
|
2008-01-03 |
2009-07-16 |
Musc Foundation For Research Development |
Methods for the treatment of cancers
|
|
WO2010118365A1
(en)
|
2009-04-10 |
2010-10-14 |
Abraxis Bioscience, Llc |
Nanoparticle formulations and uses therof
|
|
WO2009126401A1
(en)
|
2008-04-10 |
2009-10-15 |
Abraxis Bioscience, Llc |
Compositions of hydrophobic taxane derivatives and uses thereof
|
|
KR20100133475A
(ko)
|
2008-04-10 |
2010-12-21 |
아브락시스 바이오사이언스, 엘엘씨 |
소수성 탁산 유도체의 조성물 그의 용도
|
|
US20120128732A1
(en)
|
2008-12-11 |
2012-05-24 |
Vuong Trieu |
Combinations and modes of administration of therapeutic agents and combination therapy
|
|
CN102427728A
(zh)
|
2009-03-13 |
2012-04-25 |
阿布拉科斯生物科学有限公司 |
用硫代秋水仙碱衍生物进行联合治疗
|
|
PT2419732T
(pt)
|
2009-04-15 |
2019-12-24 |
Abraxis Bioscience Llc |
Composições e métodos de nanopartículas isentas de priões
|
|
CN102573832B
(zh)
*
|
2009-08-25 |
2015-07-22 |
阿布拉科斯生物科学有限公司 |
利用紫杉烷和刺猬抑制剂的纳米颗粒组合物的联合治疗
|
|
WO2011060328A1
(en)
*
|
2009-11-13 |
2011-05-19 |
Infinity Pharmaceuticals, Inc. |
Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
|
|
PL2552438T3
(pl)
|
2010-03-26 |
2016-12-30 |
|
Sposoby leczenia raka wątrobowokomórkowego
|
|
BR112012024590A2
(pt)
|
2010-03-29 |
2016-05-31 |
Abraxis Bioscience Inc |
métodos de reforço da liberação de fármaco e da eficácia de agentes terapêuticos
|
|
RU2016119999A
(ru)
|
2010-03-29 |
2018-11-08 |
АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи |
Способы лечения онкологических заболеваний
|
|
SG186109A1
(en)
|
2010-06-02 |
2013-01-30 |
Abraxis Bioscience Llc |
Methods of treating bladder cancer
|
|
CN103002905A
(zh)
*
|
2010-06-03 |
2013-03-27 |
阿布拉西斯生物科学有限责任公司 |
Sparc微环境标签在癌症治疗中的应用
|
|
JP6257324B2
(ja)
|
2010-06-04 |
2018-01-10 |
アブラクシス バイオサイエンス， エルエルシー |
膵臓がんの処置方法
|
|
EP3056201A1
(en)
|
2010-06-07 |
2016-08-17 |
Abraxis BioScience, LLC |
Combination therapy methods for treating proliferative diseases
|
|
CA3063641A1
(en)
|
2011-04-28 |
2012-11-01 |
Abraxis Bioscience, Llc |
Intravascular delivery of nanoparticle compositions and uses thereof
|
|
SMT201900502T1
(it)
|
2011-12-14 |
2019-11-13 |
Abraxis Bioscience Llc |
Uso di eccipienti polimerici per la liofilizzazione o il congelamento di particelle
|
|
US9149455B2
(en)
|
2012-11-09 |
2015-10-06 |
Abraxis Bioscience, Llc |
Methods of treating melanoma
|
|
US20140186447A1
(en)
|
2012-12-28 |
2014-07-03 |
Abraxis Bioscience, Llc |
Nanoparticle compositions of albumin and paclitaxel
|
|
US20140199404A1
(en)
|
2013-01-11 |
2014-07-17 |
Abraxis Bioscience, Llc |
Method for treating cancer based on level of a nucleoside transporter
|
|
US20140199405A1
(en)
|
2013-01-11 |
2014-07-17 |
Abraxis Bioscience, Llc |
Method for treating cancer based on mutation status of k-ras
|
|
US9511046B2
(en)
|
2013-01-11 |
2016-12-06 |
Abraxis Bioscience, Llc |
Methods of treating pancreatic cancer
|
|
JP6349381B2
(ja)
|
2013-03-12 |
2018-06-27 |
アブラクシス バイオサイエンス， エルエルシー |
肺がんを処置する方法
|
|
US20160015817A1
(en)
|
2013-03-13 |
2016-01-21 |
Abraxis Bioscience, Llc |
Methods of treatment of pediatric solid tumor
|
|
NZ630213A
(en)
|
2013-03-14 |
2017-05-26 |
Abraxis Bioscience Llc |
Methods of treating bladder cancer
|